a german firm whose main product is derived from the saliva of the vampire bat is looking to raise more than 70m euros 91m Â£49m on the stock marketits main drug desmoteplase is based on a protein in the bats salivathe firm paion said that it hoped to sell 5 million shares  a third of the firm  for 1114 euros a share
